Research library
Retatrutide Research Overview: Triple GIP/GLP-1/Glucagon Receptor Pharmacology and the Current Evidence Base
- Compiled by:
- Peptide Pilots Scientific Content Team
- Reviewed by:
- Peptide Pilots Quality & Compliance review
- Last revised:
What is currently established about retatrutide's receptor pharmacology, and how mature is the published evidence?
Retatrutide is a single-chain synthetic peptide reported to activate three receptors: GIPR, GLP1R and the glucagon receptor (GCGR). Its published receptor profile is described as GIPR-dominant with lower relative potency at GLP1R and GCGR. The rationale for adding glucagon receptor agonism is increased energy expenditure alongside incretin-mediated reductions in energy intake. The human evidence base consists mainly of phase 1 and phase 2 studies; no completed phase 3 outcome data were available at the time of this revision, so all human findings should be treated as preliminary.
This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.
What is Retatrutide?
Retatrutide is a fatty-acylated 39-amino-acid peptide based on a GIP backbone, engineered so that a single molecule engages the GIP, GLP-1 and glucagon receptors with a deliberately unbalanced potency ratio.
In laboratory work it is used as a reference triple agonist for comparative receptor assays, for studies dissecting glucagon-receptor contributions to metabolic phenotypes, and in rodent models of energy balance and hepatic lipid handling.
Retatrutide names and identifiers
Also referred to as: GLP3-RTA (catalogue designation); LY3437943; triple agonist; GGG tri-agonist
| Full chemical class | Acylated triple GIP/GLP-1/glucagon receptor agonist |
|---|---|
| Molecular formula | C221H342N46O68 |
| Average molecular weight | ≈4731 g/mol |
| Development code | LY3437943 |
| Molecular targets | GIPR (P48546), GLP1R (P43220), GCGR (P47871) |
| Registry records | ClinicalTrials.gov NCT04881760 (phase 2 obesity), NCT05929066 (TRIUMPH programme) |
Retatrutide research background
Glucagon receptor agonism has long been reported to raise energy expenditure and promote hepatic fatty-acid oxidation, but as a single agent it also raises glucose, which limited its standalone investigation.
Combining glucagon receptor agonism with incretin receptor agonism was proposed as a way to retain the expenditure-related effects while offsetting the glycaemic penalty. Early proof-of-concept came from dual GLP-1/glucagon peptides and from unimolecular tri-agonists reported in rodent models from 2015 onward.
Retatrutide is the most advanced tri-agonist in published human study. The central scientific questions are whether the glucagon component measurably increases energy expenditure in humans, whether hepatic fat reduction exceeds what weight change alone would predict, and what the long-term cardiovascular and hepatic profile looks like.
Proposed Retatrutide mechanisms and pathways
Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.
Retatrutide in-vitro and cell-based evidence
- Reported cAMP potency ranking in receptor-expressing cell lines is GIPR > GLP1R ≈ GCGR, with the glucagon-receptor component intentionally attenuated relative to native glucagon.
- As with tirzepatide, the GLP1R signalling profile has been described as biased toward cAMP with reduced β-arrestin recruitment.
Retatrutide animal-model evidence
- Rodent obesity models report greater fat-mass reduction than matched GLP-1 or dual-agonist exposure, together with reductions in hepatic triglyceride content.
- Indirect calorimetry in rodents has reported increases in energy expenditure attributable to the glucagon-receptor component, a finding that has not been unambiguously reproduced in humans.
Published Retatrutide human-study evidence
- Phase 1 studies reported a half-life supporting once-weekly dosing intervals and dose-dependent gastrointestinal events, together with transient heart-rate increases.
- A 48-week phase 2 trial in adults with obesity reported dose-dependent mean weight change up to approximately −24% at the highest dose studied.
- A phase 2 sub-study in participants with metabolic-dysfunction-associated steatotic liver disease reported large relative reductions in liver fat measured by MRI-PDFF.
Published Retatrutide studies
| Study | Model / type | Research question | Main observation | Citation |
|---|---|---|---|---|
| Coskun et al., LY3437943 discovery | In vitro receptor assays; rodent models | Can one peptide engage three receptors with a controlled potency ratio? | Reported GIPR-dominant triple agonism with attenuated GCGR potency and retained metabolic efficacy in rodents. | Cell Metabolism, 2022 |
| Urva et al., first-in-human study | Human phase 1, single and multiple ascending doses | What are the pharmacokinetics and tolerability? | Half-life consistent with weekly dosing; dose-dependent nausea and vomiting; transient heart-rate elevation. | The Lancet, 2022 |
| Jastreboff et al., phase 2 obesity trial | Human, 338 adults with obesity, 48 weeks | What weight change occurs relative to placebo? | Mean change of −17.5% to −24.2% by dose versus −2.1% with placebo. | New England Journal of Medicine, 2023 |
| Sanyal et al., liver-fat sub-study | Human phase 2 sub-population with hepatic steatosis | Does hepatic fat fall beyond expectations from weight change? | Large relative reductions in MRI-PDFF liver fat content; causal attribution to GCGR agonism remains inferential. | Nature Medicine, 2024 |
Limitations of the Retatrutide evidence
- The human evidence base is phase 2 at most for efficacy endpoints; no completed phase 3 or cardiovascular outcome data were published at the time of this revision.
- Trial durations of 48 weeks in a few hundred participants cannot characterise rare adverse events or long-term safety.
- The claimed energy-expenditure contribution of glucagon receptor agonism is supported mainly by rodent calorimetry; direct human calorimetric confirmation at therapeutic exposures is limited.
- Liver-fat findings are confounded by concurrent weight loss, so an independent hepatic mechanism is plausible but not demonstrated.
- Heart-rate increases and dose-dependent gastrointestinal effects reported in early trials require longer observation before their significance can be judged.
- Because the compound is investigational, secondary literature and vendor descriptions frequently overstate the certainty of its findings.
Retatrutide laboratory characteristics
Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.
| Appearance | White to off-white lyophilised powder |
|---|---|
| Solubility | Reported soluble in aqueous buffer at mildly alkaline pH |
| Lyophilised storage | Commonly stored at −20 °C, desiccated and light-protected |
| Reconstituted handling | Kept cold and used within short working periods; freeze–thaw cycling avoided |
| Analytical testing | RP-HPLC purity and MS identity confirmation per lot |
| Stability considerations | Acylated peptides are prone to aggregation; visual inspection for particulates is standard practice |
Frequently asked Retatrutide research questions
Which three receptors does retatrutide activate?
The GIP receptor, the GLP-1 receptor and the glucagon receptor, with a reported potency ranking that favours GIPR.
Why include glucagon receptor agonism at all?
Published rationale is that glucagon receptor activation raises energy expenditure and hepatic fatty-acid oxidation, while the incretin components offset the glucose-raising effect of glucagon alone.
Is retatrutide an approved medicine?
No. At the time of this revision it is an investigational compound in clinical development, and material supplied for research is not for human or veterinary use.
How does it compare with tirzepatide in published data?
No adequately powered head-to-head trial has been published. Cross-trial comparisons of weight endpoints are confounded by differing populations, durations and titration schemes.
Retatrutide primary references
- Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism. https://doi.org/10.1016/j.cmet.2022.07.013
- Urva S, Coskun T, Loh MT, et al. (2022). LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. The Lancet. https://doi.org/10.1016/S0140-6736(22)01592-9
- Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2301972
- Sanyal AJ, Kaplan LM, Frías JP, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine. https://doi.org/10.1038/s41591-024-03018-2
- Eli Lilly and Company (2026). TRIUMPH clinical trial programme records. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=retatrutide
Authorship and revision
Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published ; last revised . Pages are revised when the cited literature changes materially.
Catalogue reference
Peptide Pilots supplies GLP3-RTA as a laboratory reagent with per-lot RP-HPLC and mass-spectrometry documentation. Quantities, testing, packaging and fulfilment details are on the catalogue page.
Related catalogue products
Laboratory reagents supplied by Peptide Pilots from the Weight-Management Research tier. Research use only; not for human or veterinary use.
